Basic and clinical studies on cefluprenam in urinary tract infections

Koushi Sakuramoto, Ryuji Fujita, Toyohiko Watanabe, Tadasu Takenaka, Kouichi Monden, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yasuhiro Katayama, Teruaki Akaeda

Research output: Contribution to journalArticlepeer-review


We studied the antibacterial activity and clinical efficacy of cefluprenam (CFLP), a new injectable cephalosporin antibiotic, in urinary tract infections. 1) Antibacterial activity: The MICs of CFLP were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ceftazidime (CAZ), cefoperazone (CPZ), latamoxef (LMOX) and imipenem (IPM). In general, the antibacterial activity of CFLP was superior to those of other compared cephems except for IPM, but slightly inferior to that of IPM. 2) Clinical efficacy: Fourteen patients with complicated urinary tract infection were treated once or twice a day with 0.5g or 1.0g of CFLP. Out of 14, 12 cases were evaluated according to the criteria of the apanese UTI Committee. The overall clinical efficacy rate was 66.7%(8/12). Bacteriologically, 17 of 20 strains (85%) were eradicated. 3) Side effect: No clinical side effects and no abnormal laboratory changes were observed in any cases.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalJapanese Journal of Chemotherapy
Publication statusPublished - Jan 1 1995


  • cefluprenam

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Basic and clinical studies on cefluprenam in urinary tract infections'. Together they form a unique fingerprint.

Cite this